Acute flaccid paralysis

Acute flaccid paralysis denotes a syndrome of acute loss of motor tone and weakness, and in the supplied sources it is presented as a surveillance concept that can arise from multiple causes rather than a single pathogen ^[1][2][3]. Guillain-Barré syndrome is identified as the most common cause worldwide and as an immune-mediated disease of the peripheral nerves ^[2][3]. The evidence also notes that flaviviruses can cause acute flaccid paralysis among a broader spectrum of severe disease, but no single etiologic agent is established for this concept in the payload ^[1].

The clinical picture in the sources is dominated by progressive motor weakness, often preceded by an antecedent illness in the preceding weeks ^[2][3]. In Guillain-Barré syndrome, the neurologic process is described as affecting the peripheral nerves, with a demyelinating neuropathy noted as the most common type in North America ^[3]. The sources also state that autonomic instability and respiratory compromise can occur and may require close observation and intensive care ^[3]. Most patients do well with immunotherapy, but a substantial proportion are left with disability, and death can occur ^[2].

The provided evidence indicates that Guillain-Barré syndrome is the most common cause of acute flaccid paralysis worldwide, and it occurs in children around the world as well ^[2][3]. The sources also report geographical variation in Guillain-Barré syndrome, including insufficient access to immunotherapy in low-income countries ^[2]. Several infections have been associated with the syndrome, notably Campylobacter jejuni, Zika virus, and severe acute respiratory syndrome coronavirus 2 ^[2][3]. In parallel, flaviviruses are described as globally distributed and capable of emerging unexpectedly in human populations, with outbreaks including dengue virus, West Nile virus, and Zika virus ^[1].

No single transmission route is established for acute flaccid paralysis as a surveillance concept in the supplied material ^[2][3]. Where the syndrome is linked to flaviviruses, the source states that these viruses are vector-borne RNA viruses ^[1]. For Guillain-Barré syndrome, the evidence emphasizes antecedent infection and an immune-mediated mechanism rather than direct person-to-person transmission ^[2][3].

The supplied sources do not define a complete risk-group profile for acute flaccid paralysis, so source-backed detail is limited ^[2][3]. Children are specifically mentioned as affected by Guillain-Barré syndrome worldwide ^[3]. The evidence also notes geographic inequities in access to immunotherapy in low-income countries, which is relevant to outcome burden rather than susceptibility per se ^[2].

The sources do not provide a dedicated prevention strategy for acute flaccid paralysis as a syndrome, so source-backed detail on preventive measures is not yet available ^[2][3]. For Guillain-Barré syndrome, the evidence highlights the importance of improving access to immunotherapy and developing disease-modifying therapies that limit nerve injury, but it does not specify primary prevention methods ^[2]. For flaviviruses, the provided material supports the relevance of countermeasure development in response to their emerging threat, but it does not enumerate specific public-health interventions ^[1].

In surveillance practice, acute flaccid paralysis should be read as a high-priority neurologic presentation with multiple possible etiologies, rather than as a diagnosis in itself ^[1][2][3]. The sources suggest that Guillain-Barré syndrome is the principal cause to consider, but flaviviral illness and other infections are also relevant in the differential context described by the evidence ^[1][2][3]. Because the payload does not include a formal case definition, notification threshold, or reporting algorithm, those source-backed details are not yet available ^[4][5][6].

1. 1 Pierson TC et al. The continued threat of emerging flaviviruses. Nat Microbiol. 2020 Jun. PMID: 32367055. doi: 10.1038/s41564-020-0714-0. PubMed: https://pubmed.ncbi.nlm.nih.gov/32367055/
2. 2 Shahrizaila N et al. Guillain-Barré syndrome. Lancet. 2021 Mar 27. PMID: 33647239. doi: 10.1016/S0140-6736(21)00517-1. PubMed: https://pubmed.ncbi.nlm.nih.gov/33647239/
3. 3 Langille MM et al. Guillain-Barre Syndrome in Children and Adolescents. Adv Pediatr. 2023 Aug. PMID: 37422300. doi: 10.1016/j.yapd.2023.04.001. PubMed: https://pubmed.ncbi.nlm.nih.gov/37422300/
4. 4 Acute Flaccid Paralysis. ICU Protocols. 2012. doi: 10.1007/978-81-322-0535-7_29. DOI: https://doi.org/10.1007/978-81-322-0535-7_29
5. 5 Acute Flaccid Paralysis. ICU Protocols. 2025. doi: 10.1007/978-981-96-5633-2_32. DOI: https://doi.org/10.1007/978-981-96-5633-2_32
6. 6 Acute Flaccid Paralysis. ICU Protocols. 2020. doi: 10.1007/978-981-15-0898-1_31. DOI: https://doi.org/10.1007/978-981-15-0898-1_31

ICD-10

ICD-11

Total cases

9K

Peak month

2023-03

Coverage

2 reporting countries · 2007-01-01 → 2026-06-01